Longeveron LLC (LGVN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.40M
Last updated: Nov 17, 2026 at 11:03 AM ET
Longeveron LLC (LGVN) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Longeveron LLC reported EPS of -$1.91, below the -$1.70 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LGVN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
LGVN Earnings Call
The latest LGVN earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 20 quarters below that had an estimate, LGVN beat 6, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $115000, down 16.1% from $137000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.91 | -$1.70 | -$1.70 - -$1.70 | -12.35% | Miss | N/A | 1 | N/A | Nov 12, 2026 | $115000 |
| Jun 30, 2026 | -$0.19 | -$0.19 | -$0.21 - -$0.18 | 0.00% | In line | N/A | 3 | N/A | Aug 12, 2026 | $287000 |
| Mar 31, 2026 | -$0.19 | -$0.17 | -$0.23 - -$0.12 | -11.76% | Miss | N/A | 4 | 1 up, 0 down | May 13, 2026 | $398000 |
| Dec 31, 2025 | -$2.20 | -$3.67 | N/A | +40.00% | Beat | N/A | 3 | 2 up, 1 down | Mar 17, 2026 | $365000 |
| Sep 30, 2025 | -$0.39 | -$0.26 | -$0.26 - -$0.25 | -50.00% | Miss | N/A | 3 | 2 up, 1 down | Nov 4, 2025 | $137000 |
| Jun 30, 2025 | -$0.33 | -$0.35 | N/A | +5.71% | Beat | N/A | N/A | 0 up, 0 down | Aug 13, 2025 | $316000 |
| Mar 31, 2025 | -$0.34 | -$0.33 | N/A | -3.03% | Miss | N/A | N/A | 0 up, 0 down | May 8, 2025 | $381000 |
| Dec 31, 2024 | -$0.27 | -$0.20 | N/A | -35.00% | Miss | N/A | N/A | 0 up, 0 down | Feb 28, 2025 | $603000 |
| Sep 30, 2024 | -$0.34 | -$0.44 | -$0.55 - -$0.27 | +22.73% | Beat | N/A | 3 | 0 up, 0 down | Nov 12, 2024 | $773000 |
| Jun 30, 2024 | -$1.83 | -$0.87 | -$1.12 - -$0.62 | -110.34% | Miss | N/A | 2 | 2 up, 0 down | Aug 14, 2024 | $468000 |
| Mar 31, 2024 | -$1.61 | -$2.00 | -$2.70 - -$1.31 | +19.50% | Beat | N/A | 2 | 1 up, 0 down | May 14, 2024 | $548000 |
| Dec 31, 2023 | -$2.50 | -$2.05 | -$2.30 - -$1.90 | -21.95% | Miss | N/A | 2 | 0 up, 0 down | Feb 27, 2024 | $63000 |
| Sep 30, 2023 | -$2.80 | -$2.40 | -$2.40 - -$2.10 | -16.67% | Miss | N/A | 2 | 0 up, 0 down | Nov 10, 2023 | $150000 |
| Jun 30, 2023 | -$2.70 | -$2.47 | -$2.60 - -$2.40 | -9.31% | Miss | N/A | 3 | 0 up, 0 down | Aug 11, 2023 | $217000 |
| Mar 31, 2023 | -$0.22 | -$0.21 | -$0.23 - -$0.19 | -4.76% | Miss | N/A | 2 | 0 up, 0 down | May 12, 2023 | $279000 |
| Dec 31, 2022 | -$2.10 | -$2.00 | -$2.50 - -$1.00 | -5.00% | Miss | N/A | 2 | 0 up, 0 down | Mar 10, 2023 | $491000 |
| Sep 30, 2022 | -$2.50 | -$2.20 | -$2.40 - -$2.00 | -13.64% | Miss | N/A | 3 | 0 up, 0 down | Nov 14, 2022 | $265000 |
| Jun 30, 2022 | -$2.70 | -$2.27 | -$2.60 - -$1.90 | -18.94% | Miss | N/A | 3 | 0 up, 0 down | Aug 12, 2022 | $466000 |
| Mar 31, 2022 | -$1.70 | -$2.25 | -$2.40 - -$2.10 | +24.44% | Beat | N/A | 2 | 0 up, 0 down | May 13, 2022 | N/A |
| Dec 31, 2021 | -$0.20 | -$0.25 | -$0.25 - -$0.25 | +20.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 11, 2022 | $209000 |
| Sep 30, 2021 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2021 | $232000 |
| Jun 30, 2021 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2021 | $489000 |
| Mar 31, 2021 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2021 | $376000 |
| Dec 31, 2020 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | $1.18M |
| Sep 30, 2020 | -$0.66 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $1.86M |
| Jun 30, 2020 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $876000 |
| Mar 31, 2020 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | $1.71M |
| Sep 30, 2019 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.26, after -$4.05 the year before. It was -$1.05 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.26 | N/A |
| Dec 31, 2024 | -$4.05 | N/A |
| Dec 31, 2023 | -$8.22 | N/A |
| Dec 31, 2022 | -$9.00 | N/A |
| Dec 31, 2021 | -$0.89 | N/A |
| Dec 31, 2020 | -$1.05 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,500 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,461 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,636 | 8 | |
| 2025Q4 | Dec 31, 2025 | 3,516 | 8 | |
| 2025Q3 | Sep 30, 2025 | 6,412 | 10 | |
| 2025Q2 | Jun 30, 2025 | 6,973 | 10 | |
| 2024Q4 | Dec 31, 2024 | 5,019 | 8 | |
| 2024Q3 | Sep 30, 2024 | 4,232 | 8 | |
| 2024Q2 | Jun 30, 2024 | 4,513 | 7 |
2026Q2 Earnings Call
Opening remarks
Derek Cole Investor Relations Advisor Thank you, Rochelle. Good afternoon, everyone, and thank you for joining us today to review Longeveron's second quarter financial results and business update. After the U.S. markets closed today, we issued a press release with financial results for the second quarter which can be found under the Investors section of the Longeveron website. On the call today are Stephen H. Willard, Chief Executive Officer; Dr. Joshua Hare, cofounder, Chief Science Officer, and Executive Chairman of the Board; Dr. Nataliya Agafonova, Chief Medical Officer; Devin Blass, Chief Technology Officer; and Marie Washburn, Chief Financial Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Stephen H. Willard, Chief Executive Officer. Steve?
Stephen H. Willard Chief Executive Officer Thank you, Derek, and thank you all for joining us today. This is an incredibly important and exciting time for the company. Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business. As a reminder, we are developing Laromestrocel in four indications with high unmet medical needs: hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. We have focused our development activities to prioritize our most important near-term catalyst, the data readout from ELPIS II, our Phase 2b clinical trial evaluating Laromestrocel in HLHS. We expect to report that data readout in mid-September. Our approach to stem cell therapy development has garnered external recognition and validation with encouraging data from our clinical trials having been published in Nature Medicine and Cell Stem Cell. Additionally, as you hopefully saw in our announcement yesterday, published clinical trial results which indicate Laromestrocel increases six-minute walk distance in patients with aging-related frailty were the basis for our selection as a finalist for the XPRIZE HealthSpan Competition. XPRIZE HealthSpan is a seven-year, $101 million global competition to revolutionize the way we approach human aging. We are extremely humbled and appreciative to have our stem cell therapy, Laromestrocel, recognized in this manner. We believe that we are the only publicly traded company to receive this honor. XPRIZE team applications were rigorously evaluated for scientific merit and clinical readiness to identify the best, most feasible, and safe approaches to increase human health span.
Frequently Asked Questions About LGVN
Did LGVN beat earnings estimates last quarter?
No. Longeveron LLC reported EPS of -$1.91 for the quarter ended Sep 30, 2026, below the -$1.70 estimate by 12.35%.
What EPS do analysts expect from LGVN next quarter?
The consensus EPS estimate for Longeveron LLC for the quarter ending Dec 31, 2026 is -$1.73 from 4 analysts.
How often does LGVN beat earnings estimates?
Longeveron LLC beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.30%.
LGVN pages: Overview, Earnings, Forecast, Financials, Competitors